Biosimilar Trends: What 2017 May Have In Store
Potential approvals for biosimilar versions of three blockbuster products in the EU and/or the US in 2017, growing prescriber confidence in such products against the backdrop of positive switching studies, and early signs of market consolidation were some of the key trends highlighted at a recent roundtable in Mumbai.
You may also be interested in...
The CHMP has granted a positive opinion to Celltrion’s Truxima, the first biosimilar version of Roche’s cancer treatment, MabThera, but has announced the withdrawal of two pegfilgrastim products.
Germany's Merck KGaA is reportedly making soundings to sell its biosimilar business to focus on its expanding pipeline.
A senior executive shares insights around how the global logistics provider is preparing to deliver the upcoming COVID-19 vaccines across the world. While the company has prior experience with the "deep frozen" temperatures needed for some candidates, there will still be specific challenges and complexities involved.